Results 91 to 100 of about 1,056 (157)
International Medical Case Reports Journal, 2012 Abdul-Salim Ismail,1,2 Rohana Taharin,2 Zunaina Embong11Department of Ophthalmology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, 2Department of Ophthalmology, Hospital Pulau Pinang, Jalan Resindensi, Pulau Pinang ...
Ismail AS, Taharin R, Embong Z
doaj
Cyclosporin treatment of anal and perianal lesions associated with Crohn’s disease
The Turkish Journal of Gastroenterology, 2003 Hüseyin ÇAT +4 more
doaj
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Southern Medical Journal, 1986
Cyclosporine is a fungal metabolite increasingly used as an immunosuppressive agent in organ transplantation. It provides immunosuppression primarily through reversible inhibition of T-lymphocytes, without myelotoxicity. Cyclosporine appears to inhibit primary activation of helper cells and to decrease the production of lymphokines by these cells ...
S E, Thomas, D S, Gordon
openaire +2 more sources
Cyclosporine is a fungal metabolite increasingly used as an immunosuppressive agent in organ transplantation. It provides immunosuppression primarily through reversible inhibition of T-lymphocytes, without myelotoxicity. Cyclosporine appears to inhibit primary activation of helper cells and to decrease the production of lymphokines by these cells ...
S E, Thomas, D S, Gordon
openaire +2 more sources
Drug Intelligence & Clinical Pharmacy, 1985
Cyclosporine is an immunosuppressant used to prevent the rejection of transplanted kidneys, hearts, and livers. Cyclosporine suppresses T-lymphocyte function without causing myelosuppression, and its pharmacokinetics are highly variable. Compared with conventional immunosuppressive drug therapy, both patient and graft survival improved in patients ...
R J, Ptachcinski +2 more
openaire +2 more sources
Cyclosporine is an immunosuppressant used to prevent the rejection of transplanted kidneys, hearts, and livers. Cyclosporine suppresses T-lymphocyte function without causing myelosuppression, and its pharmacokinetics are highly variable. Compared with conventional immunosuppressive drug therapy, both patient and graft survival improved in patients ...
R J, Ptachcinski +2 more
openaire +2 more sources
Journal of the American Academy of Dermatology, 1986
Cyclosporin A is a new immunosuppressive agent that selectively affects T helper cells without suppressing the bone marrow. Cyclosporin A has been used primarily to prevent rejection in organ transplantation and acute graft-versus-host disease. Studies suggest that it may be of benefit in psoriasis, pemphigus vulgaris, bullous pemphigoid, Behçet's ...
E H, Page, D M, Wexler, L C, Guenther
openaire +2 more sources
Cyclosporin A is a new immunosuppressive agent that selectively affects T helper cells without suppressing the bone marrow. Cyclosporin A has been used primarily to prevent rejection in organ transplantation and acute graft-versus-host disease. Studies suggest that it may be of benefit in psoriasis, pemphigus vulgaris, bullous pemphigoid, Behçet's ...
E H, Page, D M, Wexler, L C, Guenther
openaire +2 more sources
Journal of the American Academy of Dermatology, 1989
Cyclosporine is a potent immunosuppressive agent with no appreciable effect on the bone marrow and a selective inhibitory effect on helper T cells. Oral cyclosporine was first used to prevent organ rejection but also has been reported to be effective in other disorders. In cutaneous diseases that respond to oral cyclosporine helper T cells appear to be
A K, Gupta +7 more
openaire +2 more sources
Cyclosporine is a potent immunosuppressive agent with no appreciable effect on the bone marrow and a selective inhibitory effect on helper T cells. Oral cyclosporine was first used to prevent organ rejection but also has been reported to be effective in other disorders. In cutaneous diseases that respond to oral cyclosporine helper T cells appear to be
A K, Gupta +7 more
openaire +2 more sources
Transplantation Proceedings, 2004
The concentration at 2 hours after drug intake (C2) is proposed to optimise clinical outcomes in organ transplantation and for adjustment of the regimen of cyclosporine. A population based pharmacokinetic study was undertaken during the first 30 days post-liver transplantation.
M, Billing-Grima, P, Wolf
openaire +4 more sources
The concentration at 2 hours after drug intake (C2) is proposed to optimise clinical outcomes in organ transplantation and for adjustment of the regimen of cyclosporine. A population based pharmacokinetic study was undertaken during the first 30 days post-liver transplantation.
M, Billing-Grima, P, Wolf
openaire +4 more sources